摘要
特异免疫球蛋白M(IgM)和免疫球蛋白G(IgG)抗体检测是国家卫生健康委员会"新型冠状病毒肺炎诊疗方案(试行第七版)"中新增的临床确诊手段,但是目前出现了较多的假阳性问题。本文将分析2019新型冠状病毒(2019-nCoV)特异IgM和IgG抗体检测出现假阳性的原因,探讨如何最大程度地避免抗体假阳性结果。临床上需要明确,尽管通过一些方法可以减少IgM和IgG抗体检测的假阳性,但无法完全避免。特异IgM/IgG抗体必须进行两次以上的动态检测,才能够成为新型冠状病毒肺炎在病毒核酸检测阴性情况下可靠的确诊标准。
Assays of specific immunoglobulin M(IgM)and immunoglobulin G(IgG)have been supplemented in"diagnosis and treatment guidelines of COVID-19"(7th edition)issued by National Health Commission of the People′s Republic of China as an auxiliary evidence to diagnose COVID-19.However,the false positive results is a major problem in the application of antibody assays.The factors causing the false positive results were analyzed and the ways were discussed to reduce the false positive results.The false positive results of antibody assays can be reduced,but they cannot be fully resolved.Antibody assays are valuable criteria for the diagnosis of suspected cases with negative nucleic acid results only if at least two dynamic tests are used.
作者
张瑞
李金明
Zhang Rui;Li Jinming(National Center for Clinical Laboratories,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Science,P.R.China,Beijing 100730,China)
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2020年第5期507-510,共4页
Chinese Journal of Laboratory Medicine
